VIRIDIAN THERAPEUTICS INC

10 nov. 2026, 21:02 UTC

Wells Fargo raises Viridian Therapeutics' price target to $39, while Wedbush increases its target to $44, following positive Phase 1 results for VRDN-008.

9 nov. 2026, 21:04 UTC

Viridian Therapeutics reports positive Phase 1 trial results for VRDN-008, showing a 74% reduction in IgG levels and plans for pivotal trials in mid-2027.

6 nov. 2026, 23:51 UTC

Viridian Therapeutics will host a conference call on November 9, 2026, to present data from its VRDN-008 phase 1 clinical trial and discuss development plans.

5 nov. 2026, 22:11 UTC

Viridian Therapeutics, Inc. is gaining significantly in after-market trading, reaching near the upper end of its one-month range since Thursday's close.

4 nov. 2026, 23:31 UTC

Viridian Therapeutics, Inc. shares are trading modestly higher in after-market hours, reflecting broader market gains amid resilient labor market data and geopolitical factors.

3 nov. 2026, 21:07 UTC

Viridian Therapeutics, Inc. shares declined, pulling back from an early peak, finishing modestly lower compared to Monday's close amid broader market declines.

2 nov. 2026, 20:52 UTC

Viridian Therapeutics, Inc. shares are experiencing higher trading activity today, despite diverging from a recent trend of higher daily closes since Friday.

30 oct. 2026, 20:13 UTC

Viridian Therapeutics, Inc. shares are trading sharply higher in after-market hours, maintaining a strong performance since Friday's close and above its 20-day moving average.

29 oct. 2026, 20:13 UTC

Viridian Therapeutics is set to report Q3 FY2026 earnings on November 4, with an estimated EPS of $-1.03 and projected revenue of $4.9 million.

27 oct. 2026, 19:51 UTC

Trading higher, approaching $20–$21 ahead of earnings report.

26 oct. 2026, 19:56 UTC

Viridian Therapeutics Inc is trading sharply higher, recovering from earlier lows this week and reaching its highest point of the day.

23 oct. 2026, 23:11 UTC

Viridian Therapeutics Inc saw a significant decline in after-market trading, marking its fourth consecutive session of lower closes since Friday's close.

22 oct. 2026, 20:31 UTC

Viridian Therapeutics Inc is seeing a significant decline in after-market trading, deepening its losses since Thursday's close amid unusual weakness.

21 oct. 2026, 20:07 UTC

Viridian Therapeutics Inc is trading higher, remaining significantly above its 20-day moving average, despite settling lower after reaching a peak earlier in the session.

20 oct. 2026, 20:02 UTC

Viridian Therapeutics Inc shares are advancing, maintaining a sharply higher trajectory since Monday's close despite an earlier pullback from a session high.

19 oct. 2026, 20:02 UTC

Viridian Therapeutics Inc shares are sharply higher, continuing a trend of higher daily closes since Friday's close, amid mixed performance in the biotechnology sector.

16 oct. 2026, 20:02 UTC

Viridian Therapeutics reports positive topline results from its REVEAL-2 Phase 3 trial for elegrobart, but faces increased competition from Roche's FDA-approved Enspryng.

15 oct. 2026, 20:02 UTC

Viridian Therapeutics Inc shares are higher, continuing an upward trajectory since Wednesday's close, despite an earlier pullback from a session high.

14 oct. 2026, 20:07 UTC

Viridian Therapeutics Inc shares are modestly higher, recovering from an early dip as the broader market also shows gains since Tuesday's close.

12 oct. 2026, 20:06 UTC

Viridian Therapeutics Inc shares are declining, retreating from an earlier session high and remaining well below their 20-day moving average amid ongoing weakness.

9 oct. 2026, 20:12 UTC

Viridian Therapeutics Inc shares advanced in after-market trading, holding a cumulative return of 1.19% since Friday's close.

8 oct. 2026, 20:07 UTC

Viridian Therapeutics Inc shares are slightly higher, recovering from an earlier drop, but remain below their 20-day moving average and near the lower end of their one-month range.

7 oct. 2026, 20:21 UTC

Viridian Therapeutics Inc declined during after-market hours, continuing a downward trend that began after Wednesday's close and remaining below its 20-day moving average.

6 oct. 2026, 21:03 UTC

Viridian Therapeutics Inc is rising in after-market trading, advancing from a low of roughly flat to a high gain since Tuesday's close.

2 oct. 2026, 20:07 UTC

Viridian Therapeutics Inc is advancing in today's trading session, gaining ground since Thursday's close, despite slightly retreating from an early peak.

1 oct. 2026, 20:02 UTC

Viridian Therapeutics Inc. shares fell sharply amid growing anticipation for a follow-on program, marking a departure from recent higher daily closes.

29 sept. 2026, 20:07 UTC

Viridian Therapeutics Inc. shares fell sharply, continuing a decline from Monday's close and remaining near the lower end of their one-month trading range.

25 sept. 2026, 20:07 UTC

Viridian Therapeutics Inc shares fell sharply, closing lower for the third consecutive session and remaining significantly below the 20-day moving average.

24 sept. 2026, 20:07 UTC

Viridian Therapeutics Inc shares fell sharply, finishing significantly lower than Wednesday's close and well below its 20-day moving average.

23 sept. 2026, 20:12 UTC

Viridian Therapeutics Inc saw modestly lower trading in after-market hours on Wednesday, remaining significantly below its 20-day moving average.